Funding for this research was provided by:
US Department of Energy, Office of Science Award (DE-SC0012353)
Deutsche Forschungsgemeinschaft (807122, 807454, DFG Sonderforschungsbereich 824, Project B11)
Fondation ARC pour la Recherche sur le Cancer (SAE20160604150)
Prostate Cancer Foundation (17CHAL02)
NIH-NCI (P30 CA016042)
National Cancer Institute (P50 CA092131)
Received: 21 August 2018
Accepted: 18 October 2018
First Online: 29 October 2018
: All animal studies were approved by the UCLA Animal Research Committee (ARC; # 2005-090).
: Not applicable.
: JCz and CR are co-founders and hold equity in both Sofie Biosciences and Trethera Therapeutics. Intellectual property has been patented by the University of California and has been licensed to Sofie Biosciences and Trethera Therapeutics. No other potential conflict of interest relevant to this article was reported.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.